Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ESMO 2017

8 - 12 Sep 2017
IFEMA, Feria de Madrid, Avda. del Partenón, 528042 Madrid, Spain, Madrid, Spain
Videos
News
ESMO 2017: 'Triggers': A new tool to assess cancer patients' palliative needs
ESMO 2017: 'Triggers': A new tool to assess cancer patients' palliative needs
ESMO 2017: EAPM roundtable at ESMO Congress on education, innovation and beyond
ESMO 2017: EAPM roundtable at ESMO Congress on education, innovation and beyond
ESMO 2017: Debate on duration of colon cancer adjuvant chemotherapy takes centre stage at ESMO 2017
ESMO 2017: Debate on duration of colon cancer adjuvant chemotherapy takes centre stage at ESMO 2017
ESMO 2017: Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma
ESMO 2017: Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma
ESMO 2017: KEYNOTE-040 evaluates pembrolizumab in head and neck cancer
ESMO 2017: KEYNOTE-040 evaluates pembrolizumab in head and neck cancer
ESMO 2017: Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma
ESMO 2017: Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma
ESMO 2017: Updated results of the SCOT study
ESMO 2017: Updated results of the SCOT study
ESMO 2017: Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer
ESMO 2017: Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon...
ESMO 2017: Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for Stage III colon cancer
ESMO 2017: Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for Stage III colon cancer
ESMO 2017: FOLFOX4/XELOX in stage II–III colon cancer: efficacy and safety results
ESMO 2017: FOLFOX4/XELOX in stage II–III colon cancer: efficacy and safety results
ESMO 2017: Combined lenvatinib and pembrolizumab produces notable response rates in advanced renal carcinoma
ESMO 2017: Combined lenvatinib and pembrolizumab produces notable response rates in advanced renal carcinoma
ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer
ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer
ESMO 2017: Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer
ESMO 2017: Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer
ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer
ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer
ESMO 2017: Combination immunotherapy in second/third line extends mesothelioma survival to 15 months
ESMO 2017: Combination immunotherapy in second/third line extends mesothelioma survival to 15 months
ESMO 2017: Study confirms chemoradiation is best treatment for locally advanced cervical cancer
ESMO 2017: Study confirms chemoradiation is best treatment for locally advanced cervical cancer
ESMO 2017: Cancer patients struggle with key aspects of clinical trials
ESMO 2017: Cancer patients struggle with key aspects of clinical trials
ESMO 2017: Abdominal fat a key cancer driver for postmenopausal women
ESMO 2017: Abdominal fat a key cancer driver for postmenopausal women
ESMO 2017: Licensing and reimbursement discrepancies impact patient access to cancer treatment
ESMO 2017: Licensing and reimbursement discrepancies impact patient access to cancer treatment
ESMO 2017: Study shows ESMO Magnitude of Benefit Scale can be used to grade orphan drugs
ESMO 2017: Study shows ESMO Magnitude of Benefit Scale can be used to grade orphan drugs
ESMO 2017: Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer
ESMO 2017: Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer
ESMO 2017: Durvalumab improves progression-free survival in stage III lung cancer
ESMO 2017: Durvalumab improves progression-free survival in stage III lung cancer
ESMO 2017: Patients feel psycho-social impact of chemo more acutely than physical side effects
ESMO 2017: Patients feel psycho-social impact of chemo more acutely than physical side effects
ESMO 2017: Study identifies factors that limit work ability of young adult cancer survivors
ESMO 2017: Study identifies factors that limit work ability of young adult cancer survivors
ESMO 2017: Taselisib boosts breast tumour shrinkage in LORELEI trial
ESMO 2017: Taselisib boosts breast tumour shrinkage in LORELEI trial
ESMO 2017: Promising response rate to pembrolizumab in pretreated metastatic gastric cancer
ESMO 2017: Promising response rate to pembrolizumab in pretreated metastatic gastric cancer
ESMO 2017: New data confirms superiority of docetaxel based triplet therapy in gastric cancer
ESMO 2017: New data confirms superiority of docetaxel based triplet therapy in gastric cancer
ESMO 2017: DNA sequencing could open up new drug indications for patients with rare cancers
ESMO 2017: DNA sequencing could open up new drug indications for patients with rare cancers
ESMO 2017: Patients with high risk prostate cancer may benefit “equally” from two new treatments
ESMO 2017: Patients with high risk prostate cancer may benefit “equally” from two new treatments
ESMO 2017: Rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer
ESMO 2017: Rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer
ESMO 2017: ALEX and ALUR trials of alectinib show CNS benefit in NSCLC
ESMO 2017: ALEX and ALUR trials of alectinib show CNS benefit in NSCLC
ESMO 2017: 3-year outcomes favour laparoscopic surgery for oesophageal cancer
ESMO 2017: 3-year outcomes favour laparoscopic surgery for oesophageal cancer
ESMO 2017: Study in early stage breast cancer shows that even small tumours can be aggressive
ESMO 2017: Study in early stage breast cancer shows that even small tumours can be aggressive
ESMO 2017: ICON8 trial reaffirms standard dosing in ovarian cancer chemo
ESMO 2017: ICON8 trial reaffirms standard dosing in ovarian cancer chemo
ESMO 2017: Trial results question role of CT-scan in NSCLC post-surgery follow-up
ESMO 2017: Trial results question role of CT-scan in NSCLC post-surgery follow-up

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation